-
公开(公告)号:EP4452202A1
公开(公告)日:2024-10-30
申请号:EP22844153.1
申请日:2022-12-23
申请人: Laboratoires THEA
发明人: LEBRETON, Luc
-
公开(公告)号:EP3618834B1
公开(公告)日:2024-06-26
申请号:EP18721805.2
申请日:2018-05-04
IPC分类号: A61K31/7016 , A61K31/702 , A61K31/7024 , A61K9/00 , A61P1/04 , A61P9/00 , A61P1/16 , A61P35/00 , A61P25/28 , A61P11/00 , A61P19/02 , A61P17/06 , A61P1/18 , A61P37/00 , A61P3/10 , A61P27/14 , A61P17/00
CPC分类号: A61K9/0014 , A61K9/0019 , A61K9/0031 , A61K9/0053 , A61K31/7016 , A61K31/702 , A61K31/7024 , A61P1/16 , A61P11/00 , A61P17/06 , A61P9/00 , A61P25/28 , A61P35/00 , A61P1/18 , A61P37/00 , A61P27/14 , A61P17/00 , A61P1/04 , A61P19/02 , A61P3/10
-
公开(公告)号:EP4249060A3
公开(公告)日:2024-01-03
申请号:EP23189888.3
申请日:2015-05-15
IPC分类号: A61K9/00 , A61K38/00 , A61K47/18 , A61K47/26 , A61K47/02 , A61P1/00 , A61P1/04 , A61P17/06 , A61P19/02 , A61P19/00 , A61P7/00 , A61P19/08 , A61P27/14 , A61P29/00 , A61P37/06 , C07K16/24
摘要: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazoliumhistidine), and a disaccharide sugar stabiliser. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. prefilled syringes) to reduce unnecessary waste of the drug.
-
4.
公开(公告)号:EP4268827A1
公开(公告)日:2023-11-01
申请号:EP21910965.9
申请日:2021-12-23
发明人: OGURA, Naoki , KAJIWARA, Yu , FUJISAWA, Koushi , ESAKI, Yoshihiko , SAKANAKA, Koji , FUJISAWA, Toyomi , TONE, Yuko
IPC分类号: A61K31/551 , A61K9/06 , A61K9/107 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/44 , A61P27/02 , A61P27/14 , A61P37/08
摘要: The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.
-
公开(公告)号:EP4268825A1
公开(公告)日:2023-11-01
申请号:EP21910981.6
申请日:2021-12-23
发明人: FUJISAWA, Toyomi , IKEDA, Hiroyuki
IPC分类号: A61K31/55 , A61K9/06 , A61K9/10 , A61K9/107 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/22 , A61K47/44 , A61P27/02 , A61P27/14 , A61P39/06
摘要: The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.
-
公开(公告)号:EP3197556B1
公开(公告)日:2023-11-01
申请号:EP15791737.8
申请日:2015-09-21
IPC分类号: A61K31/216 , A61K31/593 , A61K31/353 , A61P27/14 , A61K31/192 , A61K45/06 , A61P37/08 , A61K31/352 , A61K36/53 , A61K31/05 , A61K9/48 , A61K9/20 , A61K9/24 , A61K36/535
-
公开(公告)号:EP4188339A1
公开(公告)日:2023-06-07
申请号:EP21755715.6
申请日:2021-07-29
申请人: Faes Farma, S.A.
发明人: HERNÁNDEZ HERRERO, Gonzalo , ORTEGA AZPITARTE, Ignacio , MARCIANES MORENO, Patricia , TATO CERDEIRAS, Paloma , SUÑÉ NEGRE, José María , GUAL PUJOL, Francisco , ROIG CARRERAS, Manuel
IPC分类号: A61K9/20 , A61K9/24 , A61K31/137 , A61K31/454 , A61P11/02 , A61P27/14 , A61P37/08
-
公开(公告)号:EP4041264A1
公开(公告)日:2022-08-17
申请号:EP20801059.5
申请日:2020-10-06
-
公开(公告)号:EP3932421A1
公开(公告)日:2022-01-05
申请号:EP20765494.8
申请日:2020-02-28
发明人: SHIBUYA Akira , KANEMARU Kazumasa
IPC分类号: A61K39/00 , A61K45/00 , A61P1/04 , A61P11/02 , A61P11/06 , A61P27/02 , A61P27/14 , A61P27/16 , A61P37/08 , A61P17/00 , A61P17/04 , C12N5/07 , C12N15/62 , A61K38/16 , G01N33/15
摘要: The present invention provides a composition for use in treatment of an allergic disease. The present invention provides a composition for use in treatment of an allergic disease, the composition including a ligand for asialoglycoprotein receptor 1 (Asgr1).
-
公开(公告)号:EP3773645A1
公开(公告)日:2021-02-17
申请号:EP19785325.2
申请日:2019-04-09
-
-
-
-
-
-
-
-
-